Jon Faiz Kayyem bought $1.5M of Inhibrx Biosciences (INBX)
Executed Nov 19 2024, disclosed Nov 22 2024, 3 days later, against a two-business-day limit.
Over the 21 trading sessions from the disclosed entry session (Nov 22 2024), the stock returned +2.8% (delay-adjusted); from the execution session (Nov 19 2024), +4.2%. Derived: entry at the session's open, exit at the close 20 sessions later.
Jon Faiz Kayyem (Director) filed 2 Form 4 reports in the trailing twelve months (2 purchases, 0 sales), most often in Inhibrx Biosciences, Inc. (INBX). The largest single filing was $568K of INBX (5,000 sh × $113.52, as filed), executed Sep 8. The median gap between execution and disclosure was 0 days.
Healthcare · Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with…
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→5,000 sh × $100.00
Exec Sep 16
Filed Sep 17 · 5:46 PM ET INBXPURCHASE Inhibrx Biosciences, Inc. $568K
5,000 sh × $113.52
Exec Sep 8
Filed Sep 8 · 5:23 PM ET